Ascletis Initiates Participant Dosing in Phase II Trial of ASC30 for Diabetes

Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes

Topline data from the Phase II study for the treatment of diabetes are expected in the third quarter of 2026.

Ascletis initiates participant dosing in Phase II trial of ASC30 for diabetes

Ascletis Pharma has dosed the first participants in a US Phase II trial of ASC30, an oral small molecule GLP-1 receptor agonist, intended for treating type 2 diabetes mellitus.The post Ascletis initiates participant dosing in Phase II trial of ASC30 for diabetes appeared first on Clinical Trials Arena.

Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes - PressReach

Open the article to view the coverage from pressreach.com

Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes USA – English APAC – Traditional Chinese APAC – English

–Topline data from the Phase II study for the treatment of diabetes are expected in the third quarter of 2026. –ASC30 demonstrated placebo-adjusted weight loss of up to 7.7% in a recently completed 13-week U.S. Phase II study in participants with obesity or overweight, with better gastrointestinal tolerability. No hepatic safety signal was observed. HONG KONG, Jan. 25, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces t…